Department of Medical Biochemistry, College of Medicine and Medical Sciences, Arabian Gulf University, Manama, Bahrain.
Department of Medical Biochemistry, College of Medicine and Medical Sciences, Arabian Gulf University, Manama, Bahrain.
Gene. 2021 Feb 5;768:145334. doi: 10.1016/j.gene.2020.145334. Epub 2020 Dec 2.
Recurrent pregnancy loss (RPL) is a major pregnancy complication which reportedly affects 2-3% of all pregnancies. Currently, RPL lacks an effective therapy and a reliable diagnostic and prognostic biomarker. Circulating microRNAs were recently described as potential biomarkers of pregnancy-associated complications. The aim of this study was to determine microRNA expression patterns in the plasma of RPL patients as potential early biomarker of RPL. Study subjects comprised 20 women with early RPL (miscarriage at 8-12 weeks of gestation), and 20 age- and gestation-matched multiparous control women. Circulating microRNAs were extracted from maternal plasma, and the differential microRNA expression were determined using customized pathway-focused miRNA profiler kit. Of the 10 differentially-expressed microRNAs identified, Hsa-let-7e, Hsa-miR-221-3p, Hsa-miR-16, Hsa-miR-519d, Hsa-miR-184, Hsa-miR-410 were upregulated, while Hsa-miR-21, Hsa-miR-125, Hsa-let-7a, Hsa-let-7d were downregulated in RPL cases as compared to control women. Of these, 5 novel microRNAs were reported for the first time to be associated with RPL. These comprised Hsa-let-7e, Hsa-miR-519d, Hsa-miR-410 which were upregulated, and Hsa-let-7a, Hsa-let-7d which were downregulated in RPL. While its association with RPL was reported earlier, this study is also the first to report on the upregulation of Hsa-miR-184 in circulating fluids in association with RPL. The study provides for understanding circulating microRNAs expression pattern in RPL which may be involved in its pathogenesis and demonstrates their potential role as noninvasive diagnostic and prognostic biomarkers for RPL.
复发性流产(RPL)是一种主要的妊娠并发症,据报道影响了所有妊娠的 2-3%。目前,RPL 缺乏有效的治疗方法和可靠的诊断和预后生物标志物。循环 microRNAs 最近被描述为与妊娠相关并发症的潜在生物标志物。本研究旨在确定 RPL 患者血浆中的 microRNA 表达模式,作为 RPL 的潜在早期生物标志物。研究对象包括 20 名早期 RPL 患者(妊娠 8-12 周时流产)和 20 名年龄和妊娠匹配的多产妇对照妇女。从母体血浆中提取循环 microRNAs,使用定制的通路聚焦 microRNA 分析试剂盒确定差异 microRNA 表达。在鉴定的 10 个差异表达的 microRNAs 中,Hsa-let-7e、Hsa-miR-221-3p、Hsa-miR-16、Hsa-miR-519d、Hsa-miR-184、Hsa-miR-410 上调,而 Hsa-miR-21、Hsa-miR-125、Hsa-let-7a、Hsa-let-7d 在 RPL 病例中下调与对照组妇女相比。其中,有 5 种新型 microRNAs 首次报道与 RPL 相关。这些包括上调的 Hsa-let-7e、Hsa-miR-519d、Hsa-miR-410 和下调的 Hsa-let-7a、Hsa-let-7d。虽然它与 RPL 的关联以前曾有报道,但本研究也是首次报道 Hsa-miR-184 在与 RPL 相关的循环液中的上调。该研究为了解 RPL 中循环 microRNAs 的表达模式提供了依据,这些 microRNAs可能参与其发病机制,并证明了它们作为 RPL 非侵入性诊断和预后生物标志物的潜在作用。